3DMed is a platform-based, biomarker-driven biopharmaceutical company in China, its mission is to develop safe and efficacious oncology products to fulfill unmet medical needs in China through collaborations with partners around the world. 3DMed's platforms include the world largest PDC library for liver cancer, Next-Generation DNA Sequencing, and bioinformatics for large genomic data analysis. 3DMed is capable of conducting "clinical trials" in hundreds of human tumor cell-lines with clear genomic information, then identifying target patient population with biomarkers in the clinic. Prior to 3DMed, Dr. Gong served as VP of Drug Development and Regulatory Affairs of Beigene, CEO of BL Pharma, and CTO of JOINN Laboratories. From 1998 to 2008, Dr. Gong worked at US FDA as Reviewer, he conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics. Dr. Gong is member of the Drug Safety Evaluation Committee of the Chinese Pharmaceutical Association, Council member of AAALAC, Council member of Tongxieyi Club, and members of editorial board of Chinese Journal of New Drugs, and Progress in Pharmaceutical Sciences. Dr. Gong received his Ph.D. in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.
1:00 PM–2:00 PM Jun 9, 2016
Room West 3003